Tag:
Insmed
Latest Headlines
Latest Headlines
Bayer exec takes reins at J&J's troubled consumer products biz
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and Nesa Nourmohammadi (...
Insmed stock soars after FDA ends hold on key lung drug
The company's stock price skyrocketed nearly 63% to $4.40 per share as of 12:07 p.m. ET after the announcement.
Insmed shares spike after FDA lifts hold
Shares of Insmed ($INSM) shot up on Friday after the company reported that the FDA has lifted a clinical hold on its trial of Arikace, an inhalable antibiotic for lung disease. Regulators had stepped
Insmed shares nosedive as regulators demand tox study on PhIII drug
Insmed's regulatory woes with the cystic fibrosis drug Arikace are continuing this morning with the news that the FDA will not release its hold on the late-stage trial for the treatment and is now
Insmed shares crater as FDA puts a clamp on Ph3 CF study
Just seven months after completing its takeover of Transave, Insmed is reporting that the FDA has put a clinical hold on the Phase III trial of Arikace, a late-stage cystic fibrosis drug that had
Insmed shares tank on mid-stage trial failure
Insmed's lead drug failed to show efficacy in a mid-stage clinical trial of a genetic condition called myotonic muscular dystrophy and investors swiftly hammered the stock, sending down shares more
Insmed drug OK'd for ALS patients, new trial
The FDA and Insmed have hammered out a deal that will allow a limited number of patients with Lou Gehrig's disease to receive doses of Iplex. That drug is approved for growth hormone deficiency but
Merck acquires biosimilars in $130M pact
Merck signaled its clear intent to get aggressive about the biosimilar business with this morning's announcement that the pharma giant is buying Insmed's portfolio of follow-on biologics for $130
Small biotech campaigns for biogenerics law
The small biotech Insmed has been lobbying for new legislation that would clear a regulatory pathway for biosimilars. The Richmond, VA-based company wants to develop a portfolio of follow-ons and CEO
